E levated level of plasma LDL (low-density lipoprotein) cholesterol is a major causal risk factor for coronary heart disease. Statins that reduce LDL cholesterol by inhibiting HydroxymethylglutarylCoenzyme A Reductase (HMGCR) have been shown to be beneficial for both primary and secondary prevention of coronary heart disease. However, the benefits of any drugs need to be balanced against possible side effects and risks. In this context, the late emergence of evidence that statins increase risk of type 2 diabetes mellitus (T2DM), after almost 2 decades of increasing statin use and increasingly broader recommendations in guidelines, [1] [2] [3] sparked considerable debate and public controversy as to their appropriateness especially for primary prevention in relatively low-risk individuals and led to a change in statin safety labeling by the US Food and Drug Administration. 4 Could the effect of statins on risk of T2DM have been predicted earlier? Swerdlow et al 5 used a genetic approach (Mendelian randomization) to investigate this issue. They showed that 2 single-nucleotide variants (G allele of single-nucleotide polymorphism [SNP] rs17238484 and T allele of SNP rs12916) in the HMGCR gene, which were associated with lower plasma LDL cholesterol (rs17238484 G allele: −0.063 mmol/L per allele; rs12916 T allele: −0.073 mmol/L per allele), 6 were also associated with higher body weight, waist circumference, plasma insulin and glucose concentrations, and risk of T2DM. In effect, these alleles acted as partial proxies for HMGCR inhibition by statins and their analysis illustrated that if suitable data sets are available then a genetic approach can help to identify potential on-target side effects of drug treatments.
PCSK9 (proprotein convertase subtilisin/kexin type 9) blockers have emerged as a new and powerful treatment for lowering LDL cholesterol 7, 8 and, in randomized clinical trials (RCTs), have been shown to reduce cardiovascular events without any major side effects emerging 8 (ODYSSEY Outcomes ACC18: http://www.acc. org/latest-in-cardiology/clinical-trials/2018/03/09/08/02/ odyssey-outcomes). The first 2 of these agents, alirocumab and evolocumab, have been approved by the US Food and Drug Administration and the UK National Institute for Health and Care Excellence for lowering cholesterol where statins and other drugs are not tolerated or insufficient. PCSK9 is a secreted hepatic protein that binds to the LDL receptor and targets it for endocytosis and intracellular degradation, thereby reducing the number of LDL receptors at the cell surface and increasing plasma cholesterol. 9 The development of PCSK9 inhibitors was stimulated by the demonstration that nonsense mutations and other coding variants in the PCSK9 gene are associated with lower plasma LDL cholesterol and lower life-long risk of coronary heart disease. 9 Specifically, a low-frequency variant 137G -> T, replacing arginine at position 46 with leucine, is associated with a ≈15% lower (−0.497 mmol/L per copy of the allele) LDL cholesterol. 6, 10 This variant, the T allele of the SNP, rs11591147, can therefore act as a proxy for PCSK9 inhibition by PCSK9 inhibitors, in a similar fashion to the HMGCR variants for statins. For PCSK9 inhibitors, although trials to date have not found evidence of an increase in T2DM risk in those on treatment, this has only been assessed on a relatively short follow-up of only 3 to 4 years 8 (ODYSSEY Outcomes ACC18: http://www.acc.org/latest-in-cardiology/clinicaltrials/2018/03/09/08/02/odyssey-outcomes). Indeed, initial Mendelian randomization studies have shown that genetic risk scores including this variant or other variants at the PCSK9 locus associated with lower LDL cholesterol are also associated with increased risk of T2DM raising the possibility that, as with statins, this side effect may emerge with longer use of PCSK9 blockers. 11, 12 No study has yet explored the full spectrum of long-term potential side effects of PCSK9 inhibitors using a genetic approach.
UK Biobank is a large (≈500 000 individuals) national health research resource established to understand the genetic and environmental determinants of adult diseases. 13 DNAs of UK Biobank participants have been assayed using a specially designed array providing, after imputation, genome-wide genotypes on over 70 million SNPs. Genotype data on around 480 000 of the participants have been released. The availability of these data together with the extensive phenotypic data on the participants allows a detailed exploration to see if the PCSK9 rs11591147 T variant is associated with any of a wide range of diseases or traits which may indicate other potential on-target effects of long-term inhibition PCSK9 inhibitors and inform their use. Here, we have undertaken such an analysis and at the same time reexamined the associations of the 2 HMGCR SNPs studied by Swerdlow et al 5 with body mass index (BMI) and T2DM as well as a broader range of diseases.
METHODS
The methods are available in the Data Supplement. The data that support the findings of this study are available from C.P. Nelson upon reasonable request. The UK Biobank study was approved by the Northwest Research Ethics Committee, and all participants provided informed consent (https://www. ukbiobank.ac.uk).
RESULTS
In total, we analyzed phenotype and genotype information on up to 479 522 individuals in UK Biobank. The demographic characteristics of the subjects are shown in Table 1 . The mean age at recruitment was 56.5 years (range, 37-73), 54.2% were female, and 5.3% reported a non-white ethnic background. Several participants were taking lipid-lowering medication (17.6%) and blood pressure (BP)-lowering medication (21.0%).
The number of individuals with the various disorders/ traits that we analyzed is shown in Table 2 . These include both prevalent cases (ie, those reported at the time of enrollment) and subsequent cases as recorded in hospital episode statistics or in disease registries. The proportion of each disorder based on reported history only (ie, not recorded in the available hospital episode statistics data or in registries) are also shown in Table 2 .
The allele frequency of the PCSK9 rs11591147 T allele was 1.67% (n=15 862 carriers), whereas the frequencies for the HMGCR alleles at rs17238484 (G allele) and rs12916 (T allele) that are associated with lower LDL cholesterol were 77.0% (n=453 891 carriers) and 59.9% (401 891 carriers), respectively. All variants were well imputed (Info score, 1 for rs11591147 and rs17238484 and 0.997 for rs12916), and all SNPs were in Hardy-Weinberg equilibrium. The demographic characteristics of individuals carrying different number of copies of these variants are shown in Table II in the Data Supplement.
Consistent with their known association with lower LDL cholesterol levels, all variants were associated with a lower odds of the carriers being on lipid-lowering medication (Tables 3 and 4 ). The effect size was greater for the PCSK9 rs11591147 T allele (Table 3) , than for either of the HMGCR alleles (Table 4) , reflecting its greater effect on LDL cholesterol. Significant associations with other diseases and traits, after adjustment for lipid-lowering medication and other variables described in Methods and allowing for multiple testing, for the PCSK9 rs11591147 T allele and the lead HMGCR variant (either rs17238484 G allele or rs12916 T allele) are shown in Tables 3 and 4 , respectively. Full results for all diseases and traits analyzed are shown in Tables III through V in the Data Supplement for models with and without adjustment for lipid-lowering medication.
The PCSK9 rs11591147 T allele was associated with a higher risk of T2DM as well as higher BMI, waist circumference, and waist-hip ratio (WHR; Table 3 ). There was a consistent 7.2% (3.0%-11.6%) higher odds of obesity (BMI >30 kg/m 2 ). The PCSK9 rs11591147 T allele was also associated with an average 0.33 mm Hg (95% CI, 0.16-0.50 mm Hg) higher diastolic BP (DBP) and a greater use of BP-lowering medication. Interestingly, there was also a significant association between the PCSK9 rs11591147 T allele and type 1 diabetes mellitus and use of insulin (Table 3) , P=3.07×10 −4 and P=3.29×10 −4 , respectively. Finally, the PCSK9 rs11591147 T allele was associated with lower risk of CAD (Table 3 ). This association was stronger (odds ratio [OR], 0.676; 95% CI, 0.619-0.738; P=2.625×10 −18 ) without adjustment for lipid-lowering medication (Table III in the Data Supplement).
Regional association plots around the PCSK9 gene for T2DM, CAD, BMI, WHR, and DBP are shown in Figure I in the Data Supplement. From these analyses, it is clear that rs11591147 is the lead associated variant in the region for all the above traits except BMI where a second stronger signal is present (rs144932160). Adjusting for rs144932160 did not remove the association with rs11591147 (β, 0.153; 95% CI, 0.076-0.260; P=9.23×10 −5 ). The associations that were significant for the 2 HMGCR variants were largely very similar to those for the PCSK9 rs11591147 T allele except that the effect sizes were generally smaller. The result for the variant showing the strongest association is shown in Table 4 with full results in Tables IV and V in the Data Supplement. Both HMGCR variants were associated with increased risk of T2DM as well as higher BMI, waist circumference, WHR, obesity, as well as increased systolic BP, risk of hypertension, risk of stroke, and use of BP-lowering medication. There were nominal associations (P=0.04) of both HMGCR variants with risk of type 1 diabetes mellitus (Tables IV and V in the Data Supplement). The HMGCR rs12916 T allele was also nominally associated with risk of CAD (OR, 0.970; 95% CI, 0.951-0.990; P=0.003) which was attenuated after adjustment for lipid-lowering medication (Table V in the Data Supplement). However, for all the traits/diseases, except for T2DM and stroke, there were other SNPs in the region not in high linkage disequilibrium with our lead variants which showed a stronger association ( Figure II in the Data Supplement). Adjusting for these variants led to an attenuation of the associations with the lead variants ( Table 4 , joint estimates). Notably, the associations with BMI, waist circumference, WHR, and systolic BP all became nonsignificant, although the association with history of hypertension and BP medication persisted. For traits significantly associated with PCSK9 rs11591147 T allele, analyses stratified by lipid-lowering medication use showed consistent effects in both groups (Table VI in the Data Supplement) with only CAD risk, as expected, being attenuated in the lipid-lowering medication strata. This suggests our results are not because of collider bias. Similarly, for the HMGCR variants, we observe significant associations in both strata for the 4 traits-T2DM, stroke, hypertension, and BP medication-that were still associated with our HMGCR variants after adjusting for other variants in the region (Table VII in the Data Supplement).
To investigate if the observed associations between rs11591147 and T2DM and DBP are mediated through effects on adiposity, we considered both BMI and WHR as potential mediators. We found that the association of the variant on DBP became nonsignificant after adjusting for BMI (P=0.480) or WHR (P=0.543). On the other hand, the association with T2DM risk remained largely unchanged after further adjusting for BMI (OR, 1.26; 95% CI, 1.16, 1.37) or WHR (OR, 1.24; 95% CI, 1.15-1.35). In formal mediation analysis, we found that the direct association of rs11591147 with T2DM had an OR=1.24 (95% CI, 1.14-1.34) and the indirect effect through BMI to have an OR=1.02 (95% CI, 1.01-1.03). The proportion of the association of rs11591147 Diastolic blood pressure was adjusted for antihypertensive medication as described by Tobin et al. 14 The associations for quantitative traits are shown as β coefficients and for categorical disorders as odds ratios. The full analysis with all traits and disorders is shown in Table III . Model results are from a mixed model adjusting for age, sex, BiLEVE chip, principle components 1-5, and lipid-lowering medication as fixed effects and family structure as a random effect.
†This model did not further adjust for lipid-lowering medication.
with T2DM that was mediated was estimated to be just 0.09% with BMI and 3.14% with WHR. The PCSK9 rs11591147 T allele is associated with a 0.497 mmol/L lower LDL cholesterol on average. 6 The PCSK9 antibody blocker evolocumab has been reported to reduce LDL cholesterol by an average of 1.81 mmol/L (70 mg/dL) over standard therapy, which may or may not have included lipid-lowering medications. 8 Therefore, if the association of PCSK9 inhibition with risk of T2DM was driven entirely through and proportionate to its LDL-lowering effect then we would estimate the increased risk of T2DM with evolocumab to be 2.47 (1.89-3.35)-fold higher. When given on top of lipid-lowering medication, as in the FOURIER trial, 15 evolocumab further reduced cholesterol on average by 50 mg/dL (1.295 mmol/L). This would result in an increased odds ratio of risk of T2DM of 1.90 (95% CI, 1.57-2.36).
DISCUSSION
Major side effects of drugs are sometimes identified during their initial clinical evaluation and more systematically during RCTs when they are compared with placebo. However, many RCTs are of relatively short duration and may not pick up side effects that are weak and only emerge during longer-term therapy. The evidence that statin therapy is associated with an increased risk of T2DM only emerged late in the context of its widespread clinical use and raised considerable professional and public concern and debate. [1] [2] [3] Use of genetic variants as unconfounded instruments (Mendelian randomization) to clarify whether observed epidemiological associations between biomarkers and disease are causal or not, particularly as a means of is identifying reliable therapeutic targets, is gaining increasing traction. 16 In an extension of this approach, Swerdlow et al 5 demonstrated that such genetic instruments could also help to flag up potential longer term on target side effects of drugs by showing that variants in the HMGCR gene associated with lower LDL cholesterol were also associated with T2DM.
Because the genetic instruments used in such analysis usually have a subtle effect on the target gene (unlike the drug), large data sets are required to discern any association with a downstream side effect. Unless a specific side effect is being evaluated, such data sets should also ideally inform on a broad variety of outcomes. In this regard, the UK Biobank cohort 13 offers an excellent resource because of its scale and comprehensiveness as well as the availability of genetic data. Using UK Biobank, we confirmed the association of LDL-lowering variants in the HMGCR gene with T2DM and also found, as reported recently, 10, 11 that genetic variation at the PCSK9 locus associated with increased risk of T2DM. Therefore, despite no such signal emerging in the trials of PCSK9 blockers to date, which have been of a duration of ≤48 months, 8, 15 one should anticipate that with longer-term use of such drugs T2DM is likely to emerge as a side effect. If the effect is related to the level of LDL lowering we may except to see an ≈2-fold increase in risk of T2DM.
An important consideration, especially when considering the joint association of a variant with multiple Results for the 2 HMGCR variants analyzed were very similar (Tables IV and V in the Data Supplement) and only result for the single-nucleotide polymorphism (SNP) showing the stronger association is shown. Systolic blood pressure was adjusted for antihypertensive medication as described by Tobin et al. 14 The associations for quantitative traits are shown as β coefficients and for categorical disorders as odds ratios. The full analyses with all traits and disorders are shown in Tables IV and V in the Data Supplement. Joint estimate is the association of the lead variant after adjustment for other common SNPs in the region not in high linkage disequilibrium with the lead SNP showing a stronger association with the trait. BMI indicates body mass index; and LDL, low-density lipoprotein.
*Significance based on a Bonferroni-adjusted P Value of <6.25×10 −4 . Model results are from a mixed model adjusting for age, sex, BiLEVE chip, principle components 1-5, and lipid-lowering medication as fixed effects and family structure as a random effect.
traits, is to exclude the possibility that 1 (or more) of the associations is actually because of a stronger effect of a linked variant with the association found with the selected variant representing a spillover association. In their study of the 2 HMGCR variants, Swedlow et al 5 also observed an association with BMI and waist circumference and proposed that the association of the variants (and by inference lipid-lowering medication) with T2DM may be mediated via a primary association with insulin resistance and central adiposity. Here, we clearly show that although the G allele of rs17238484 and the T allele of rs12916 are independently associated with T2DM, their association with anthropometric traits is confounded. In contrast to the HMGCR variants, PCSK9 rs11591147 has the strongest association in the region not only for T2DM but also for WHR and DBP. There was 1 stronger signal for BMI, but adjusting for this did not substantially attenuate the association of rs11591147 with BMI. This suggests that unlike the HMGCR variants, rs11591147 has primary associations with anthropometric traits. We therefore explored to what extent these associations mediate the association with DBP and T2DM. This analysis showed that although the association of rs11591147 T allele with DBP may be mediated via central adiposity, the association with T2DM is largely independent.
The lead variants were all highly significantly associated with lower use of lipid-lowering medication (Tables 3 and 4) validating their use as proxies for such treatment. Because of the potential confounding effect of such treatment on disease risk mediated by the genotype, we adjusted for use of lipid-lowering medication in our primary analysis. Indeed, the association of PCSK9 rs11591147 T allele with risk of CAD was partly attenuated by such adjustment (Table III in the Data Supplement). On the other hand, several of the observed associations were substantially stronger or only emerged when adjustment was made for lipidlowering medication (Tables III through V in the Data  Supplement) . Although likely to reflect the true association of genotype with disease/trait, it raises the possibility of collider bias whereby conditioning on a common effect (LDL-lowering medication) of a pair of variables (genotype and trait) may cause a spurious association between them. 17 To investigate this possibility, we undertook association analyses stratified by lipid-lowering medication use for those traits/diseases showing an association in the primary analysis (Tables  VI and VII in the Data Supplement) . Although the proportion of disease cases or mean values of the quantitative traits differed in individuals taking or not taking lipid-lowering medication, we found associations in both groups indicating that the observed associations are not because of collider bias (Tables VI and VII in  the Data Supplement) . Recently, large-scale genome wide association studies across a wide range of phenotypes in UK Biobank, including T2DM, CAD, BMI, WHR, and DBP, have been reported (https://biobank engine.stanford.edu/ and https://data.broadinstitute. org/alkesgroup/UKBB/). These analyses include the 3 variants studied here and report associations similar to our analyses unadjusted for lipid-lowering medication. Our findings emphasize the potential importance of considering confounders when interpreting the results of such genome wide analyses.
The PCSK9 rs11591147 T allele was associated with a higher risk of not only T2DM but also type 1 diabetes mellitus. The association of this allele also with increased use of insulin (Table 3) suggests that this disease association is genuine. The mechanism for the association is unclear. It should be noted that although the main site of PCSK9 expression is in the liver, it is also expressed in several other tissues including the small intestine, colon, kidney, and cerebellum. 18 Furthermore, PCSK9 null mice display hypoinsulinemia, hyperglycemia, and glucose intolerance and have pancreatic islet abnormalities. 19 PCSK9 inhibitors have been shown to be particularly efficacious in lowering LDL cholesterol in patients with familial hypercholesterolemia. 20 Childhood initiation of lipid-lowering medication is recommended by guidelines in patients with FH (https://www.nice.org.uk/guidance/ cg71/resources/familial-hypercholesterolaemia-identification-and-management-pdf-975623384005), and the possible risk of precipitating type 1 diabetes mellitus in this group by treatment with PCSK9 blockers needs to be born in mind.
A potentially reassuring finding from our analysis is that apart from the associations discussed above, we did not observe any other major safety signals across a broad range of systems, including cancers and dementia, for either the PCSK9 rs11591147 T allele or indeed the HMGCR variants. The findings with respect to the latter are consistent with the established safety profile of statins. For the PCSK9 rs11591147 T allele, the only other conditions that achieved association of nominal significance were peptic ulcer disease (OR, Table III in the Data Supplement). Because of multiple testing, these associations should be viewed with caution, but nonetheless, the incidence of these conditions should be particularly monitored in future clinical trials and longer-term safety monitoring of anti-PCSK9 therapy.
Although not the major objective of our study, our analysis also allows us to comment on whether anti-PCSK9 therapy may have cardiovascular benefits beyond reducing risk of CAD. In this regard, we found no evidence of that the PCSK9 rs11591147 T was protective toward risk of stroke (OR, 0.923; 95% CI, 0.833-1.024; P=0.130 before adjustment for lipid-lowering medication and OR, 1.056; 95% CI, 0.949-1.176; P=0.314 after adjustment). For aortic valve stenosis (AVS), there was a trend toward a protective association (OR, 0.732; 95% CI, 0.555-0.965; P=0.027 before adjustment for lipid-lowering medication and OR, 0.837; 95% CI, 0.634-1.106; P=0.210 after adjustment). A protective association of this variant on risk of AVS has also been reported by others. 21 LDL lowering through statins has not been found to reduce the rate of progression of AVS. 22 However, anti-PCSK9 therapy also lowers Lp(a) (lipoprotein(a)) levels, 8 and both genetic and biomarker studies support a causal role of Lp(a) in the etiology of AVS. 23, 24 Therefore, our genetic findings support the possibility that anti-PCSK9 therapy may be beneficial in preventing the development or progression of AVS.
Several limitations and caveats of our analysis need to be highlighted. First, in trying to identify potential side effects (or additional benefits), we are extrapolating any impact of a life-long (including developmental) exposure to a relatively modest genetic reduction in PCSK9 gene activity to that which might occur from a much more powerful drug inhibition of the protein products of the genes over a shorter-term time frame in adults. As an extension to this, if the side effects are dependent on the degree of inhibition, then major side effects may not be detectable in genetic analysis despite large data sets. Second, although UK Biobank currently provides the largest and most comprehensive data set to investigate potential side effects using a genetic approach, the number of cases for several disorders is still small reducing the power to detect (or exclude) associations that may be clinically relevant. This will improve with time as UK Biobank accrues more cases. Third, UK Biobank is made up predominantly of white individuals (≈95%), and we were unable to analyze for any ethnic-specific associations. Finally, genetic analysis of the type undertaken here does not allow off-target effects of the drugs (ie, those not related to inhibition of the primary target) to be identified and which may be molecule specific.
In summary, we show that despite their favourable short-term profile and clear benefit in terms of reducing cardiovascular events, longer-term use of anti-PCSK9 therapy is likely to be associated with the development of several features of metabolic syndrome. These include a higher risk of T2DM and possibly insulin-requiring diabetes mellitus. Beyond this, we did not find any evidence for any other major longer-term on-target side effects, although our power to identify potentially clinically meaningful associations for some of the diseases was limited.
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